AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

CRON · NASDAQ · Drug Manufacturers - Specialty & Generic

Cronos Group

Branded cannabis portfolio across Canada, Israel, and other international markets.

$3.38

After-hours close+0.00 (+0.14%)

At close$3.38(−0.44%)

Something off on this page? Send us feedback.

Profile

Cronos Group Inc.CRONHealth Care

Sells cannabis flower and extracts under Spinach, PEACE NATURALS, and Lord Jones across Canada, Israel, and other international markets. Its current consumer-brand business follows exits from U.S. hemp-derived products and fermentation-based manufacturing.

Sells branded cannabis products through Spinach, PEACE NATURALS, and Lord Jones, including flower, pre-rolls, vaporizers, edibles, and tinctures in their applicable markets. Revenue comes from cannabis flower and extracts in Canada, Israel, and other international markets. Its portfolio spans multiple legal-market product forms.

Operates after a multiyear reset that ended U.S. hemp-derived cannabinoid sales and fermentation-based cannabinoid manufacturing. Current operations are organized around legal cannabis markets and consumer brands rather than former hemp and fermentation businesses. A proposed acquisition of Dutch CanAdelaar remained pending, subject to regulatory and other closing conditions.

Company facts

CEOMichael Gorenstein

ListedFeb 27, 2018

ExchangeNASDAQ

HeadquartersStayner, ON

CountryCanada

Employees610

CIK0001656472

ISINCA22717L1013

Key statistics

Market cap$1.26B

EPS (ttm)$0.1811

P/E (ttm)18.66

ROE6.5%

P/B1.18

P/S7.03

Dividend yield—

Beta0.77vs XLV 0.20

Year to date +25.0% · Average volume (30d) 1.5M

Analysts

Price target, next 12 months$2.90−14.2%Median of 15 analysts · vs the Aug 28 close

ConsensusHold3 of 15 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $3.38

High$4.50+33.1%

Median$2.90−14.2%

Low$2.30−32.0%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Target
Jan 14, 2026	Bernstein	Target	$2.30

Earnings

EPS

Estimate$0.03

ReportedDue Nov 5, 2026

Revenue

Estimate$49.5M

ReportedDue Nov 5, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 6, 2026Q2 FY26	$0.01	$0.09	+800.0%	$44.2M	$53.0M	+19.9%	+12.87%
May 11, 2026Q1 FY26	$0.01	$0.01	0.0%	$42.2M	$45.2M	+7.1%	+0.73%
Feb 26, 2026Q4 FY25	$0.01	$0.00	−147.0%	$38.7M	$44.5M	+15.0%	0.00%
Nov 6, 2025Q3 FY25	$0.02	$0.07	+250.0%	$38.4M	$36.3M	−5.5%	+0.40%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$32.3M	$33.5M	$36.3M	$91.3M	$44.6M	$70.6M
Gross profit	$13.7M	$14.5M	$18.3M	$16.2M	$18.5M	$28.5M
Operating income	−$4.1M	−$5.3M	−$503.0K	$7.0M	−$1.4M	$7.4M
Net income	$6.1M	−$39.7M	$26.0M	−$1.8M	$13.6M	$32.1M
Diluted EPS	$0.02	−$0.10	$0.07	−$0.00	$0.04	$0.08
Gross margin	42.6%	43.4%	50.4%	17.7%	41.4%	40.3%
Operating margin	-12.6%	-15.9%	-1.4%	7.6%	-3.2%	10.5%

Fiscal years (4-quarter sums)FY21 $84.5M · FY22 $107.3M · FY23 $87.2M · FY24 $117.6M · FY25 $193.4M

Revenue by product · Q2 FY26

Cannabis Flower$39.2M · 74%

Cannabis Extracts$13.8M · 26%

Product And Service, Other$19.0K · 0%

Revenue by geography · Q2 FY26

Canada$28.7M · 54%

Israel$15.0M · 28%

Other Countries$9.3M · 18%

Balance sheet, Jun 30, 2026Cash & short-term investments $797.0M · Total debt $1.3M · Total assets $1.18B · Shareholders' equity $1.07B

Dividends

No dividends on record.

Ownership

Institutions 12.70%47.46M sharesInsiders 4.00%14.94M sharesOther 83.30%311.26M shares

Shares outstanding 373.66M · Float 192.24M · 51.5% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Michael Ryan Gorenstein · director, officer: See remarks below	13.21M	3.54%	Form 4	Mar 17, 2026
D. E. Shaw & Co., Inc.	8.84M	2.37%	13F	Aug 14, 2026
Chescapmanager LLC	7.94M	2.13%	13F	Aug 14, 2026
Toroso Investments, LLC	3.77M	1.01%	13F	Aug 13, 2026
Dimensional Fund Advisors LP	3.05M	0.82%	13F	Aug 11, 2026

Insider tradesForm 4

No open-market trades in the last 12 months.